Hints and tips:
...Illumina bought cancer test developer Grail for $8bn in 2021, even though US and EU authorities complained the US gene sequencer could deny crucial inputs to Grail’s rivals....
...She is also a cheerleader for this emerging field of medical science, telling CNBC in December that three listed companies in the space — Intellia, Crispr Therapeutics and Editas — represent a “trillion...
...Meanwhile, US start-up Intellia Therapeutics has successfully treated the first patients using a Crispr gene-editing therapy directed inside the body to an internal organ — a breakthrough, with the technology...
...The Celgene takeover is the largest of several significant pharma and healthcare deals in the first quarter, with others including Roche’s $4.8bn purchase of gene therapy company Spark Therapeutics and Johnson...
...Editas is developing an experimental gene-editing system known as CRISPR-Cas9, which scientists hope could be used to remove and replace defective genes....
International Edition